Physicochemical Properties And Cholesterol-Lowering Mechanisms Of Powdered Phytosterol Esters (II)

1 Industrial Value of Powdered Phytosterol Esters

2 Core Physicochemical Properties and Processing Adaptability

3 Mechanistic Analysis of Cholesterol-Lowering Efficacy

3.1 Competitive Inhibition: "Spatial Competition" at the Molecular Level

The core mechanism of phytosterol esters in lowering cholesterol lies in their competitive inhibition with cholesterol in the intestines. This process begins at the stage of mixed micelle formation. During digestion, bile acids and phospholipids encapsulate dietary lipid components (including cholesterol and phytosterol esters) into mixed micelles, which act as carriers to transport hydrophobic molecules to the brush border membrane of intestinal epithelial cells.

Phytosterol esters are hydrolyzed by esterases in the intestines to release free phytosterols. Due to their highly similar structure to cholesterol but stronger hydrophobicity, phytosterols competitively occupy the limited space in micelles, reducing the incorporation of cholesterol into micelles. This is analogous to phytosterol molecules occupying the "seats" originally belonging to cholesterol on limited "transport vehicles," resulting in a reduction in the amount of cholesterol that can be delivered to intestinal absorptive cells.

3.2 Transporter Competition: "Molecular Race" for Absorption Channels

When mixed micelles approach the brush border membrane of intestinal epithelial cells, the NPC1L1 protein on the membrane acts as the main transporter, responsible for importing cholesterol and phytosterols into the cells. Due to their structural similarity, phytosterols can also be recognized and transported by NPC1L1, leading to competition between the two for the same "entry point."

Notably, there is a crucial difference in the human body's handling of phytosterols and cholesterol: the intestinal absorption rate of cholesterol can reach 30%-60%, while that of phytosterols is usually less than 2%. This difference mainly stems from variations in subsequent processing mechanisms.

3.3 Differential Disposal by Efflux Pumps: A Critical Selective Barrier

After entering intestinal epithelial cells, cholesterol and phytosterols face a critical divergence point-the ABCG5/ABCG8 efflux pump. This pair of retrotransporter proteins located on the apical membrane of cells can pump absorbed sterol molecules back into the intestinal lumen.

The key point is that the ABCG5/ABCG8 efflux pump exhibits a clear preference for excreting phytosterols-it actively expels phytosterols from cells, while its efficiency in excreting cholesterol is relatively low. This difference results in phytosterols being almost "sent back," while most cholesterol remains in the cells. The molecular basis for this differential disposal lies in the additional alkyl side chain on the C24 position of phytosterols; although these structural differences are small, they are sufficient to be recognized by the ABCG5/ABCG8 protein.

3.4 Intracellular Esterification and Packaging: Blockage of Metabolic Pathways

Even if a small amount of phytosterols successfully evades the efflux pump, they will face another metabolic barrier. Within intestinal cells, the ACAT2 enzyme is responsible for esterifying free cholesterol, which is then packaged into chylomicrons and enters the lymphatic system. However, ACAT2 has extremely low esterification efficiency for phytosterols, meaning phytosterols are difficult to be packaged into chylomicrons.

This mechanism further ensures that phytosterols do not enter the circulatory system in large quantities. Meanwhile, since ACAT2 and MTP (microsomal triglyceride transfer protein) are also responsible for the esterification and packaging of cholesterol, the processing of phytosterols by these enzymes can indirectly affect the normal metabolic pathways of cholesterol.

3.5 Systemic Regulation: Adaptive Changes in Hepatic Cholesterol Metabolism

Competitive inhibition at the intestinal level leads to reduced cholesterol absorption, triggering a series of systemic responses. When the liver senses a decrease in cholesterol "supply" from the intestines, it upregulates the expression of LDL receptors through the SREBP-2 pathway, increasing the uptake of circulating LDL particles by hepatocytes, thereby reducing blood LDL-C levels.

At the same time, the liver attempts to compensate by increasing endogenous cholesterol synthesis and enhancing HMG-CoA reductase activity. This mechanism explains the synergistic effect when phytosterols are used in combination with statins (HMG-CoA reductase inhibitors)-the two act on the absorption and synthesis pathways of cholesterol metabolism respectively, achieving a "dual-pronged" regulatory effect.

4 Efficacy-Influencing Factors and Synergistic Strategies